2023年
- December 8, 2023
- Imidafenacin for Overactive Bladder Launched in Mexico
- November 8, 2023
- Notice of differences between Forecasts and Actual Results
- November 8, 2023
- Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Nov 8, 2022) - Supplementary Information
- November 8, 2023
- Summary of Consolidated Financial Results(For second quarter ended September 30, 2023) [Japanese GAAP]
- September 29, 2023
- Notice Regarding Implementation of voluntary Retirement Program
- August 2, 2023
- 1Q Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 (August 02, 2023) - Supplementary Information
- August 2, 2023
- Summary of Consolidated Financial Results(For the first quarter ended June 30, 2023) [Japanese GAAP]
- May 22, 2023
- Notice of Dividends of Retained Earnings
- May 11, 2023
- Summary of Consolidated Financial Results(For fiscal year ended May 11, 2023) [Japanese GAAP]
- May 11, 2023
- Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (May 11, 2023) - Supplementary Information
- May 11, 2023
- Kyorin Announces New Long-Term Vision "Vision 110" and Medium-Term Business Plan "Vision 110 -Stage 1-"
- May 11, 2023
- Notice of Relocation of Head Office
- April 27, 2023
- KYORIN website has been relaunched today.
- April 3, 2023
- Notice of Absorption Type Merger of Wholly Owned Subsidiary KYORIN Pharmaceutical Co., Ltd and Change of Trade Name
- March 6, 2023
- KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian Countries
- 1